✦ LIBER ✦

Willingness to Pay for Improvements in Chronic Long-Acting Insulin Therapy in Individuals With Type 1 or Type 2 Diabetes Mellitus

✍ Scribed by Andrew Lloyd; Beenish Nafees; Anthony H. Barnett; Simon Heller; Uffe J. Ploug; Morten Lammert; Mette Bøgelund

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PDB22 ECONOMIC EVALUATION OF LONG-ACTING

✍ D Belanger; CG Cameron 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

Use of rapid-acting insulin analogues in

✍ Bruce W. Bode 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 216 KB

PDB21 ECONOMIC EVALUATION OF RAPID-ACTIN

✍ D Belanger; CG Cameron 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB

Lack of association of CPT1A polymorphis

✍ Yushi Hirota; Takeshi Ohara; Masako Zenibayashi; Shin-ichi Kuno; Keiko Fukuyama; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 175 KB

Replacement of neutral protamine Hagedor

✍ Taro Hayakawa; Michiyo Ishii; Megumi Watanabe; Hiroya Iwase; Asako Nishimura; Ta 📂 Article 📅 2010 🏛 Wiley (Blackwell Publishing) 🌐 English ⚖ 103 KB

Amylin replacement with pramlintide as a

✍ R. E. Ratner; R. Dickey; M. Fineman; D. G. Maggs; L. Shen; S. A. Strobel; C. Wey 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 168 KB